These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25579771)

  • 1. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
    Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A
    Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
    Schaefer B; Würtinger P; Finkenstedt A; Braithwaite V; Viveiros A; Effenberger M; Sulzbacher I; Moschen A; Griesmacher A; Tilg H; Vogel W; Zoller H
    PLoS One; 2016; 11(12):e0167146. PubMed ID: 27907058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
    Barea Mendoza JA; Gredilla Zubiría I; González Olmedo J; Mateo Alvarez S
    Med Clin (Barc); 2014 Sep; 143(6):284-5. PubMed ID: 24461741
    [No Abstract]   [Full Text] [Related]  

  • 9. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
    Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
    Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
    Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
    J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: A rare cause of severe hypophosphatemia.
    Román-Gimeno S; Ortez-Toro JJ; Peteiro-Miranda CM; Sanz-Martín B; Urdaniz-Borque R
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):125-126. PubMed ID: 32409006
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis.
    Bellos I; Frountzas M; Pergialiotis V
    Transfus Med Rev; 2020 Jul; 34(3):188-194. PubMed ID: 32819760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.
    Befrits R; Wikman O; Blomquist L; Hjortswang H; Hammarlund P; Bajor A; Klintman D; Blom H
    Scand J Gastroenterol; 2013 Sep; 48(9):1027-32. PubMed ID: 23889159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T; Bedouch P; Zaoui P
    Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.